Penumbra (NYSE:PEN) announced additional results from its STORM-PE trial of computer-assisted vacuum thrombectomy (CAVT).

NEW YORK - Penumbra, Inc. (NYSE:PEN), a $9.87 billion medical technology company with strong financial health and ~13% revenue growth over the last twelve months, announced Monday that its computer ...

Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in pulmonary embolism swept away in favor of mechanical thrombectomy. A ...

Penumbra, Inc. announced that results of the STORM-PE randomized controlled trial (RCT) were presented at VIVA 2025, the Vascul ...

Shares of medical device company Penumbra (NYSE:PEN) jumped 17.2% in the morning session after it reported third-quarter 2025 financial results that surpassed Wall Street's expectations for both ...

Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results from its landmark STORM-PE randomized controlled trial. The study found that ...

Q3 2025 Earnings Call Transcript November 5, 2025 Penumbra, Inc. beats earnings expectations. Reported EPS is $0.97, expectations were $0.9. Operator: Ladies and gentlemen, good afternoon. My name is ...

Penumbra, Inc. announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVTtm) with ...

ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical ...

The global Neurovascular Devices Market, valued at US$4.27 billion in 2024, stood at US$4.64 billion in 2025 and is projected ...